Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer (TRIOC)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2016 by University College, London
Oxford BioMedica
Cancer Research UK
Information provided by (Responsible Party):
University College, London Identifier:
First received: March 14, 2012
Last updated: June 3, 2016
Last verified: June 2016
The purpose of this trial is to assess the effectiveness of TroVax® compared to placebo in extending the time to progression in patients with asymptomatic relapsed platinum resistant ovarian, fallopian tube or primary peritoneal cancer.The trial will also look at overall survival times and quality of life.

Condition Intervention Phase
Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer
Biological: TroVax®
Biological: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised Parallel Group Double-Blind Phase II Study to Assess the Activity of TroVax® (MVA-5T4) Versus Placebo in Patients With Relapsed Asymptomatic Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Resource links provided by NLM:

Further study details as provided by University College, London:

Primary Outcome Measures:
  • Progression [ Time Frame: At 25 weeks ]
    RECIST-defined progression

Secondary Outcome Measures:
  • Immune-related response criteria (irRC) [ Time Frame: 8 weeks post evidence of progression by RECIST 1.1 ]
    irRC will be used to identify any delayed response.Patients will remain on treatment until irRc has confirmed progression (in the absence of unacceptable toxicity or the need for urgent chemotherapy).

  • Progression-free survival [ Time Frame: Time from randomisation to clinical intervention or confirmed evidence of progression or death, assessed for up to 2 years ]
  • Time to clinical intervention [ Time Frame: Time from randomisation to clinical intervention or death, assessed for up to 2 years ]
  • Incidence of clinical intervention [ Time Frame: At 25 weeks from randomisation ]
  • CA-125 doubling time [ Time Frame: Assessed at treatment visits for up to 2 years from randomisation. ]
    To investigate CA-125 doubling time as an independent prognostic factor.

  • Overall survival [ Time Frame: Time between randomisation and death assessed for up to 4 years ]
  • Quality of Life [ Time Frame: For up to 2 years following randomisation or until progression ]
    Patient reported outcome and health-related quality of life measured by standardised questionnaires (EORTC QLQ C-30, EORTC QLQ OV-28)

Estimated Enrollment: 75
Study Start Date: November 2013
Estimated Study Completion Date: October 2018
Estimated Primary Completion Date: May 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TroVax®
TroVax® consists of a highly attenuated VV (Modified Vaccinia Ankara, MVA) containing the human TAA 5T4 under regulatory control of a modified VV promoter, mH5.
Biological: TroVax®
Patients will be randomised to receive either TroVax® 1 x 10↑9 TCID50/mL in 1mL (experimental arm) or matched placebo (control arm) on a 1:1 basis. A single dose will be given by intramuscular injection during the following weeks: 2, 4, 7, 10, 13, 19, 25, 31, 37, 43 and 49. No further treatment will be given beyond week 49.Treatment will be stopped early if confirmed progression or unacceptable toxicity.
Placebo Comparator: Placebo Biological: Placebo
Matched placebo will be administered as above.

Detailed Description:

A significant number of patients with advanced ovarian cancer develop a "CA-125 relapse" without clinical symptoms and with a low volume disease on the CT scan. For this group of patients, no survival benefit has been demonstrated from early chemotherapy treatment and, on average, the time to start of chemotherapy is 5 months. Such patients could benefit from immunotherapy and the time to chemotherapy could potentially be prolonged. Multiple immunotherapy agents, such as anti-CA-125 antibodies and various vaccines, have been tested and, although there is plenty of evidence of immune response, this has not translated to a definitive clinical benefit and is not recommended in clinical practice

5T4 appears to be highly expressed in ovarian cancer and correlates with more advanced stage of disease and poorly differentiated tumours. TroVax®, the vaccine targeting 5T4, has an extensive record of safety and efficacy in humans and vaccination in patients with colorectal, renal, and prostate cancer resulted in immune cellular and humoral responses and signs of clinical benefit.

We propose a trial of TroVax® vaccination in patients with CA-125-relapsed asymptomatic ovarian cancer to assess the clinical efficacy and immunological responses as outlined in this protocol. To allow for capture of any delayed response to immunotherapy, patients who progress on RECIST 1.1 criteria and who do not experience toxicity from treatment will continue on the vaccine/placebo injection until repeat imaging at 8 weeks in order for immune-related response criteria (irRC) to be evaluated in addition to RECIST 1.1 criteria (these patients as a standard of care would not receive any other therapeutic intervention).


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Aged ≥18 years with histologically or cytologically proven advanced epithelial ovarian carcinoma, fallopian tube carcinoma or primary peritoneal carcinoma
  • Stage IC1 - III or Stage IVA (pleural effusion only) at diagnosis. (According to new FIGO staging effective 01/01/2014)
  • Completed cytoreductive surgery during the phase of first-line therapy including removal of bulky tumour masses and adequate surgical staging including a minimum of bilateral salpingo-oophorectomy, hysterectomy and omentectomy
  • Completed first line platinum-based chemotherapy OR Completed first line platinum-based chemotherapy and second line chemotherapy of any type with complete response to second line treatment according to RECIST 1.1
  • Have developed relapse ≥6 months after platinumbased chemotherapy (in the case of second relapse, the disease free interval should also be ≥6 months)
  • Normal CA-125 following platinum-based chemotherapy
  • Have developed asymptomatic relapse as defined by:

    1. CA125 ≥ 2xULN OR
    2. Low volume radiological disease and CA125>ULN Low volume radiological disease is defined as radiologically visible disease excluding intra-hepatic (parenchymal) liver or splenic metastases, ascites or pleural effusion thought to require drainage within the next 2 months. The following are acceptable: Subcapsular liver and splenic lesions, benign lesions or cysts, any suspicious lesions that may represent metastases have to be confirmed by further imaging to be non-metastatic.
  • Currently asymptomatic and does not require chemotherapy.
  • Subject is assumed to be clinically immunocompetent and is free of clinically apparent/active autoimmune disease (i.e. no prior confirmed diagnosis or treatment for autoimmune disease including Systemic Lupus Erythematosis, Grave's disease, Hashimoto's thyroiditis, multiple sclerosis, and rheumatoid arthritis). Note: subjects with type I or type II diabetes mellitus can be included, as can subjects with controlled and rarely flaring rheumatoid disease (defined as recent flare within 6 months prior to randomisation)
  • Subject has adequate bone marrow function as defined by Haemoglobin ≥ 110 g/L, white cell count ≥ 3.0 x 10^9/L, Absolute Lymphocyte Count (ALC) ≥ 1.0 x 10^9/L, Absolute Neutrophil Count (ANC) ≥1.5 x 10^9/L , Platelet Count ≥ 100 x 10^9/L and <400 x 10^9/L, Monocytes <0.8 x 10^9/L (for patients who have undergone previous splenectomy monocyte counts can be < 1.2 x 10^9/L)
  • Adequate end-organ function: plasma creatinine ≤ 2x upper limit of normal, AST and/or ALT ≤ 2x upper limit of normal, Total Bilirubin ≤ 1.5x upper limit normal
  • ECOG performance status 0-1
  • Life expectancy ≥6 months and willing to be available to attend clinic visits for treatment and for follow-up
  • Ability to give written informed consent
  • To be treated no later than 14 days from randomisation

Exclusion Criteria:

  • Carcino-sarcoma/MMMT
  • Cancer related symptoms, or disease recurrence requiring immediate treatment
  • Patients with low volume radiological disease in any of the following sites at trial entry:
  • Accumulating ascites thought to require drainage within the next 2 months
  • Pleural effusion thought to require drainage within the next 2 months
  • Intraparenchymal Liver and/or splenic metastases
  • CT scan showing bulky disease requiring chemotherapy, as judged by the investigator
  • Major surgery/radiation therapy, immunotherapy or chemotherapy completed < 4 weeks prior to randomisation
  • Patients who are deemed as being immunosuppressed, receiving > 4 weeks parenteral or oral steroids, (nasal sprays and inhalers are permitted), or receiving immunosuppressive therapy following transplant
  • Chronic (≥ 6 months) oral corticosteroid use except when prescribed as replacement therapy in the case of adrenal insufficiency. If previously used for ≥6 months then must have discontinued ≥3 months prior to randomisation.
  • "Currently active" second malignancy, other than non-melanoma skin cancer. Subjects are not considered to have a "currently active" malignancy if they have completed therapy ≥3 years previously and have no known evidence of residual or recurrent disease
  • Concomitant use of complementary medicines/botanicals. Supplements and conventional multivitamins are acceptable.
  • Evidence of significant clinical disorder or laboratory finding which in the opinion of the investigator makes it undesirable for the patient to participate in the trial. No participant should have a serious or uncontrolled intercurrent infection (including those positive for HIV, hepatitis B or C)
  • Psychiatric illnesses/social situations that limit compliance with protocol requirements
  • Allergy to egg proteins or history of allergic response to vaccinia vaccines
  • Prior exposure to TroVax®
  • Cerebral metastases (known from previous investigations or clinically detectable, surgically resected)
  • Patients on active treatment as part of another clinical trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01556841

Contact: Kate Frost +44 2076799016
Contact: Yen Ngai +44 2076799747

United Kingdom
Leeds Teaching Hospitals NHS Trust Recruiting
Leeds, West Yorkshire, United Kingdom, LS9 7TF
Principal Investigator: Geoff Hall         
The Clatterbridge Cancer Centre NHS Foundation Trust Recruiting
Bebington, Wirral, United Kingdom, CH63 4JY
Principal Investigator: Rosie Lord         
Brighton and Sussex NHS Foundation Trust Not yet recruiting
Brighton, United Kingdom, BN2 5BE
Principal Investigator: Rebecca Herbertson         
University Hospitals of Bristol NHS Foundation Trust Recruiting
Bristol, United Kingdom, BS2 8ED
Principal Investigator: Axel Walther         
Velindre NHS Trust Recruiting
Cardiff, United Kingdom, CF14 2TL
Principal Investigator: Louise Hanna         
Beatson West of Scotland Cancer Centre Recruiting
Glasgow, United Kingdom, G12 0YN
Principal Investigator: Ros Glasspool         
Royal Surrey County Hospital NHS Foundation Trust Recruiting
Guildford, United Kingdom, GU2 7XX
Principal Investigator: Agnieszka Michael         
University College London Hospitals NHS Foundation Trust Recruiting
London, United Kingdom, NW1 2PG
Principal Investigator: Rebecca Kristeleit         
The Christie NHS Foundation Trust Recruiting
Manchester, United Kingdom, M20 4BX
Principal Investigator: Andrew Clamp         
Nottingham University Hospitals NHS Trust Recruiting
Nottingham, United Kingdom, NG5 1PB
Principal Investigator: Anjana Anand         
Oxford University Hospitals NHS Trust Recruiting
Oxford, United Kingdom, OX3 7LE
Principal Investigator: Shibani Nicum         
Plymouth Hospitals NHS Trust Recruiting
Plymouth, United Kingdom, PL6 8OH
Principal Investigator: Dennis Yiannakis         
Sponsors and Collaborators
University College, London
Oxford BioMedica
Cancer Research UK
Principal Investigator: Agnieszka Michael, MBBS, PhD University of Surrey; Royal Surrey County Hospital NHS Foundation Trust
  More Information

Additional Information:
Responsible Party: University College, London Identifier: NCT01556841     History of Changes
Other Study ID Numbers: UCL/11/0119
Study First Received: March 14, 2012
Last Updated: June 3, 2016

Keywords provided by University College, London:

Additional relevant MeSH terms:
Ovarian Neoplasms
Fallopian Tube Neoplasms
Peritoneal Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Fallopian Tube Diseases
Abdominal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Peritoneal Diseases processed this record on April 28, 2017